Weekly Digest - 01-07 Apr 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 01-07 Apr 2023
05 Apr 2023: Lynparza (Olaparib) / Imfinzi (Durvalumab) / Ovarian Cancer / AstraZeneca: Phase 3 DUO-O trial met the primary endpoint of progression-free survival
AstraZeneca reported encouraging topline data from the Phase 3 DUO-O trial evaluating the combination of Lynparza (Olaparib), Imfinzi (Durvalumab), Chemotherapy, and Bevacizumab in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without BRCA mutations
The clinical findings confirmed that the combination therapy statistically improved progression-free survival (PFS) more than a combination of Chemotherapy and Bevacizumab
- In an additional arm, Imfinzi, chemotherapy plus Bevacizumab showed a numerical improvement in PFS versus the control arm but did not reach statistical significance at this interim analysis
The safety and tolerability of the combinations were broadly consistent with observations from prior clinical trials and the known profiles of the individual therapies
The overall survival (OS) and other secondary endpoints of the trial were not mature at the time of the interim assessment and the company intends to formally assess at a subsequent analysis
